Table of Contents
1.1. Context
1.2. Project Objectives
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations on the Industry
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross Border Dynamics
4.3. Conclusion
5.1. Executive Summary: Market Landscape
5.2. Executive Summary: Market Trends
5.3. Executive Summary: Market Forecast and Opportunity Analysis
6.1. Chapter Overview
6.2. Overview of Radiopharmaceuticals
6.3. Mechanism of Action of Radiopharmaceuticals
6.4. Types of Radiopharmaceuticals
6.5. Applications of Radiopharmaceuticals
6.6. Advantages of Radiopharmaceuticals
6.7. Challenges in Radiopharmaceutical Development and Clinical Use
6.8. Recent Trends in the Radiopharmaceuticals Domain
8.1. Methodology and Key Parameters
8.2. Approved Radiopharmaceuticals: Therapy Programs
8.2.1. Analysis by Format of Radiopharmaceutical
8.2.2. Analysis by Type of Radioisotope
8.2.3. Analysis by Type of Emitter
8.2.4. Analysis by Purpose of Radiopharmaceutical
8.2.5. Analysis by Therapeutic Area
8.2.6. Analysis by Target Indication
8.2.7. Analysis by Route of Administration
8.2.8. Analysis by Dosing Frequency
8.3. Approved Radiopharmaceuticals: Developer Landscape
8.3.1. Analysis by Year of Establishment
8.3.2. Analysis by Company Size
8.3.3. Analysis by Location of Headquarters
8.3.4. Most Active Players: Analysis by Number of Approved Radiopharmaceuticals
9.1. Methodology and Key Parameters
9.2. Clinical and Preclinical Radiopharmaceuticals: List of Therapy Programs
9.2.1. Analysis by Stage of Development
9.2.2. Analysis by Type of Radioisotope
9.2.3. Analysis by Type of Emitter
9.2.4. Analysis by Purpose of Radiopharmaceutical
9.2.5. Analysis by Type of Therapy
9.2.6. Analysis by Route of Administration
9.2.7. Analysis by Target Indication
9.2.8. Analysis by Therapeutic Area
9.2.9. Analysis by Target Patient Population
9.3. Clinical and Preclinical Radiopharmaceuticals: Developer Landscape
9.3.1. Analysis by Year of Establishment
9.3.2. Analysis by Company Size
9.3.3. Analysis by Location of Headquarters
9.3.4. Most Active Players: Analysis by Number of Clinical and Preclinical Radiopharmaceuticals
10.1. 3BP Pharmaceuticals
10.1.1. Company Overview
10.1.2. Management Team
10.1.3. Radiopharmaceuticals Pipeline
10.1.4. Recent Initiatives
10.2. Curium
10.3. ITM Radiopharma
10.4. Jubilant Radiopharma
10.5. Lantheus
10.6. Yantai LNC Biotechnology
10.7. Norroy Biosciences
10.8. Sinotau Pharmaceutical
10.9. Telix Pharmaceuticals
11.1. Methodology and Key Parameters
11.2. Partnership Models
11.3. Radiopharmaceuticals: Partnerships and Collaborations
11.3.1. Analysis by Year of Partnership
11.3.2. Analysis by Type of Partnership
11.3.3. Analysis by Year and Type of Partnership
11.3.4. Analysis by Type of Radioisotope
11.3.5. Analysis by Type of Emission
11.3.6. Analysis by Type of Molecule
11.3.7. Analysis by Therapeutic Area
11.3.8. Analysis by Purpose of Radiopharmaceutical
11.3.9. Analysis by Type of Partner
11.3.10. Most Active Players: Analysis by Number of Partnerships
11.3.11. Analysis by Local and International Agreements
11.3.12. Analysis by Intercontinental and Intracontinental Agreements
12.1. Methodology and Key Parameters
12.2. Radiopharmaceuticals: Clinical Trial Analysis
12.2.1. Analysis by Trial Registration Year
12.2.2. Analysis by Trial Status
12.2.3. Analysis by Trial Registration Year and Trial Status
12.2.4. Analysis of Patient Enrolled by Trial Registration Year
12.2.5. Analysis by Trial Phase
12.2.6. Analysis of Patient Enrolled by Trial Phase
12.2.7. Analysis by Type of Sponsor / Collaborator
12.2.8. Analysis by Study Design
12.2.9. Analysis by Patient Gender
12.2.10. Analysis by Target Patient Population
12.2.11. Most Active Industry Players: Analysis by Number of Clinical Trials
12.2.12. Most Active Non-Industry Players: Analysis by Number of Clinical Trials
12.2.13. Geographical Distribution: Analysis by Number of Trials and Patients Enrolled
12.2.14. Analysis by Trial Status and Geography
12.2.15. Analysis of Patients Enrolled by Trial Status and Geography
13.1. Megatrends Analysis: An Overview of the Emerging Trends
13.1.1. Expansion of Targeted Alpha Therapies (TATs)
13.1.2. Integration of AI in Radiopharmaceuticals Development
13.1.3. Advent of Theranostics
13.1.4. Expanding Applications across Diverse Indications
13.1.5. Innovations in Supply Chain and Infrastructure Advancement
13.1.6. Rise in Strategic Collaborations and Investments
14.1. Chapter Overview
14.2. Market Drivers
14.3. Market Restraints
14.4. Market Opportunities
14.5. Market Challenges
14.6. Conclusion
15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. Radiopharmaceuticals Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
15.3.1. Scenario Analysis
15.3.1.1. Conservative Scenario
15.3.1.2. Optimistic Scenario
15.4. Key Market Segmentations
16.1. Radiopharmaceuticals Market: Distribution by Type of Radioisotope
16.1.1. Radiopharmaceuticals Market for Technetium-99m, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
16.1.2. Radiopharmaceuticals Market for Leutetium-177, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
16.1.3. Radiopharmaceuticals Market for Fluorine-18, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
16.1.4. Radiopharmaceuticals Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
17.1. Radiopharmaceuticals Market: Distribution by Type of Emitter
17.1.1. Radiopharmaceuticals Market for Gamma Emitters, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
17.1.2. Radiopharmaceuticals Market for Beta Emitters, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
17.1.3. Radiopharmaceuticals Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
18.1. Radiopharmaceuticals Market: Distribution by Purpose of Radiopharmaceuticals
18.1.1. Radiopharmaceuticals Market for Diagnostics, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
18.1.2. Radiopharmaceuticals Market for Therapeutics, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
19.1. Radiopharmaceuticals Market: Distribution by Type of Diagnostic Radiopharmaceuticals
19.1.1. Radiopharmaceuticals Market for PET Imaging Agents, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
19.1.2. Radiopharmaceuticals Market for SPECT Imaging Agents, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
20.1. Radiopharmaceuticals Market: Distribution by Type of Production Method
20.1.1. Radiopharmaceuticals Market for Nuclear Reactors, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
20.1.2. Radiopharmaceuticals Market for Accelerators / Cyclotrons, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
20.1.3. Radiopharmaceuticals Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
21.1. Radiopharmaceuticals Market: Distribution by Therapeutic Area
21.1.1. Radiopharmaceuticals Market for Oncological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
21.1.2. Radiopharmaceuticals Market for Cardiovascular Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
21.1.3. Radiopharmaceuticals Market for Neurological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
21.1.4. Radiopharmaceuticals Market for Hormonal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
21.1.5. Radiopharmaceuticals Market for Gastrointestinal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
21.1.6. Radiopharmaceuticals Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
22.1. Radiopharmaceuticals Market: Distribution by End-user
22.1.1. Radiopharmaceuticals Market for Hospitals, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
22.1.2. Radiopharmaceuticals Market for Diagnostic Centers, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
22.1.3. Radiopharmaceuticals Market for Research Institutes, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
23.1. Radiopharmaceuticals Market: Distribution by Geographical Regions
23.2. Radiopharmaceuticals Market in North America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
23.2.1. Radiopharmaceuticals Market in the US, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
23.2.2. Radiopharmaceuticals Market in Canada, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
23.3. Radiopharmaceuticals Market in Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
23.3.1. Radiopharmaceuticals Market in Germany, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
23.3.2. Radiopharmaceuticals Market in France, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
23.3.3. Radiopharmaceuticals Market in Spain, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
23.3.4. Radiopharmaceuticals Market in Italy, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
23.3.5. Radiopharmaceuticals Market in the UK, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
23.3.6. Radiopharmaceuticals Market in Rest of Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
23.4. Radiopharmaceuticals Market in Asia-Pacific, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
23.4.1. Radiopharmaceuticals Market in Australia, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
23.4.2. Radiopharmaceuticals Market in China, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
23.4.3. Radiopharmaceuticals Market in Japan, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
23.4.4. Radiopharmaceuticals Market in India, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
23.4.5. Radiopharmaceuticals Market in South Korea, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
23.4.6. Radiopharmaceuticals Market in Rest of Asia-Pacific, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
23.5. Radiopharmaceuticals Market in Latin America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
23.5.1. Radiopharmaceuticals Market in Brazil, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
23.5.2. Radiopharmaceuticals Market in Rest of Latin America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
23.6. Radiopharmaceuticals Market in Middle East and North Africa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
23.6.1. Radiopharmaceuticals Market in Israel, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
23.6.2. Radiopharmaceuticals Market in South Africa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
23.6.3. Radiopharmaceuticals Market in Rest of Middle East and North Africa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
24.1 Radiopharmaceuticals Market in North America: Distribution by Type of Radioisotope
24.1.1. Radiopharmaceuticals Market in North America for Technetium-99m, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
24.1.2. Radiopharmaceuticals Market in North America for Leutetium-177, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
24.1.3. Radiopharmaceuticals Market in North America for Fluorine-18, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
24.1.4. Radiopharmaceuticals Market in North America for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
24.2. Radiopharmaceuticals Market in North America: Distribution by Type of Emitter
24.2.1. Radiopharmaceuticals Market in North America for Gamma Emitters, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
24.2.2. Radiopharmaceuticals Market in North America for Beta Emitters, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
24.2.3. Radiopharmaceuticals Market in North America for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
24.3. Radiopharmaceuticals Market in North America: Distribution by Purpose of Radiopharmaceutical
24.3.1. Radiopharmaceuticals Market in North America for Diagnostics, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
24.3.2. Radiopharmaceuticals Market in North America for Therapeutics, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
24.4. Radiopharmaceuticals Market in North America: Distribution by Type of Diagnostic Radiopharmaceutical
24.4.1. Radiopharmaceuticals Market in North America for PET Imaging Agents, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
24.4.2. Radiopharmaceuticals Market in North America for SPECT Imaging Agents, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
24.5. Radiopharmaceuticals Market in North America: Distribution by Type of Production Method
24.5.1. Radiopharmaceuticals Market in North America for Nuclear Reactors, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
24.5.2. Radiopharmaceuticals Market in North America for Accelerators / Cyclotrons, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
24.5.3. Radiopharmaceuticals Market in North America for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
24.6. Radiopharmaceuticals Market in North America: Distribution by Therapeutic Area
24.6.1. Radiopharmaceuticals Market in North America for Oncological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
24.6.2. Radiopharmaceuticals Market in North America for Cardiovascular Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
24.6.3. Radiopharmaceuticals Market in North America for Neurological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
24.6.4. Radiopharmaceuticals Market in North America for Hormonal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
24.6.5. Radiopharmaceuticals Market in North America for Gastrointestinal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
24.6.6. Radiopharmaceuticals Market in North America for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
24.7. Radiopharmaceuticals Market in North America: Distribution by End-user
24.7.1. Radiopharmaceuticals Market in North America for Hospitals, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
24.7.2. Radiopharmaceuticals Market in North America for Diagnostic Centers, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
24.7.3. Radiopharmaceuticals Market in North America for Research Institutes, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
25.1 Radiopharmaceuticals Market in Europe: Distribution by Type of Radioisotope
25.1.1. Radiopharmaceuticals Market in Europe for Technetium-99m, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
25.1.2. Radiopharmaceuticals Market in Europe for Leutetium-177, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
25.1.3. Radiopharmaceuticals Market in Europe for Fluorine-18, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
25.1.4. Radiopharmaceuticals Market in Europe for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
25.2. Radiopharmaceuticals Market in Europe: Distribution by Type of Emitter
25.2.1. Radiopharmaceuticals Market in Europe for Gamma Emitters, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
25.2.2. Radiopharmaceuticals Market in Europe for Beta Emitters, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
25.2.3. Radiopharmaceuticals Market in Europe for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
25.3. Radiopharmaceuticals Market in Europe: Distribution by Purpose of Radiopharmaceutical
25.3.1. Radiopharmaceuticals Market in Europe for Diagnostics, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
25.3.2. Radiopharmaceuticals Market in Europe for Therapeutics, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
25.4. Radiopharmaceuticals Market in Europe: Distribution by Type of Diagnostic Radiopharmaceutical
25.4.1. Radiopharmaceuticals Market in Europe for PET Imaging Agents, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
25.4.2. Radiopharmaceuticals Market in Europe for SPECT Imaging Agents, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
25.5. Radiopharmaceuticals Market in Europe: Distribution by Type of Production Method
25.5.1. Radiopharmaceuticals Market in Europe for Nuclear Reactors, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
25.5.2. Radiopharmaceuticals Market in Europe for Accelerators / Cyclotrons, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
25.5.3. Radiopharmaceuticals Market in Europe for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
25.6. Radiopharmaceuticals Market in Europe: Distribution by Therapeutic Area
25.6.1. Radiopharmaceuticals Market in Europe for Oncological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
25.6.2. Radiopharmaceuticals Market in Europe for Cardiovascular Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
25.6.3. Radiopharmaceuticals Market in Europe for Neurological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
25.6.4. Radiopharmaceuticals Market in Europe for Hormonal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
25.6.5. Radiopharmaceuticals Market in Europe for Gastrointestinal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
25.6.6. Radiopharmaceuticals Market in Europe for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
25.7. Radiopharmaceuticals Market in Europe: Distribution by End User
25.7.1. Radiopharmaceuticals Market in Europe for Hospitals, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
25.7.2. Radiopharmaceuticals Market in Europe for Diagnostic Centers, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
25.7.3. Radiopharmaceuticals Market in Europe for Research Institutes, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
26.1 Radiopharmaceuticals Market in Asia-Pacific: Distribution by Type of Radioisotope
26.1.1. Radiopharmaceuticals Market in Asia-Pacific for Technetium-99m, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
26.1.2. Radiopharmaceuticals Market in Asia-Pacific for Leutetium-177, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
26.1.3. Radiopharmaceuticals Market in Asia-Pacific for Fluorine-18, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
26.1.4. Radiopharmaceuticals Market in Asia-Pacific for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
26.2. Radiopharmaceuticals Market in Asia-Pacific: Distribution by Type of Emitter
26.2.1. Radiopharmaceuticals Market in Asia-Pacific for Gamma Emitters, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
26.2.2. Radiopharmaceuticals Market in Asia-Pacific for Beta Emitters, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
26.2.3. Radiopharmaceuticals Market in Asia-Pacific for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
26.3. Radiopharmaceuticals Market in Asia-Pacific: Distribution by Purpose of Radiopharmaceutical
26.3.1. Radiopharmaceuticals Market in Asia-Pacific for Diagnostics, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
26.3.2. Radiopharmaceuticals Market in Asia-Pacific for Therapeutics, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
26.4. Radiopharmaceuticals Market in Asia-Pacific: Distribution by Type of Diagnostic Radiopharmaceutical
26.4.1. Radiopharmaceuticals Market in Asia-Pacific for PET Imaging Agents, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
26.4.2. Radiopharmaceuticals Market in Asia-Pacific for SPECT Imaging Agents, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
26.5. Radiopharmaceuticals Market in Asia-Pacific: Distribution by Type of Production Method
26.5.1. Radiopharmaceuticals Market in Asia-Pacific for Nuclear Reactors, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
26.5.2. Radiopharmaceuticals Market in Asia-Pacific for Accelerators / Cyclotrons, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
26.5.3. Radiopharmaceuticals Market in Asia-Pacific for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
26.6. Radiopharmaceuticals Market in Asia-Pacific: Distribution by Therapeutic Area
26.6.1. Radiopharmaceuticals Market in Asia-Pacific for Oncological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
26.6.2. Radiopharmaceuticals Market in Asia-Pacific for Cardiovascular Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
26.6.3. Radiopharmaceuticals Market in Asia-Pacific for Neurological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
26.6.4. Radiopharmaceuticals Market in Asia-Pacific for Hormonal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
26.6.5. Radiopharmaceuticals Market in Asia-Pacific for Gastrointestinal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
26.6.6. Radiopharmaceuticals Market in Asia-Pacific for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
26.7. Radiopharmaceuticals Market in Asia-Pacific: Distribution by End-user
26.7.1. Radiopharmaceuticals Market in Asia-Pacific for Hospitals, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
26.7.2. Radiopharmaceuticals Market in Asia-Pacific for Diagnostic Centers, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
26.7.3. Radiopharmaceuticals Market in Asia-Pacific for Research Institutes, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
27.1 Radiopharmaceuticals Market in Latin America: Distribution by Type of Radioisotope
27.1.1. Radiopharmaceuticals Market in Latin America for Technetium-99m, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
27.1.2. Radiopharmaceuticals Market in Latin America for Leutetium-177, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
27.1.3. Radiopharmaceuticals Market in Latin America for Fluorine-18, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
27.1.4. Radiopharmaceuticals Market in Latin America for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
27.2. Radiopharmaceuticals Market in Latin America: Distribution by Type of Emitter
27.2.1. Radiopharmaceuticals Market in Latin America for Gamma Emitters, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
27.2.2. Radiopharmaceuticals Market in Latin America for Beta Emitters, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
27.2.3. Radiopharmaceuticals Market in Latin America for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
27.3. Radiopharmaceuticals Market in Latin America: Distribution by Purpose of Radiopharmaceutical
27.3.1. Radiopharmaceuticals Market in Latin America for Diagnostics, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
27.3.2. Radiopharmaceuticals Market in Latin America for Therapeutics, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
27.4. Radiopharmaceuticals Market in Latin America: Distribution by Type of Diagnostic Radiopharmaceutical
27.4.1. Radiopharmaceuticals Market in Latin America for PET Imaging Agents, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
27.4.2. Radiopharmaceuticals Market in Latin America for SPECT Imaging Agents, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
27.5. Radiopharmaceuticals Market in Latin America: Distribution by Type of Production Method
27.5.1. Radiopharmaceuticals Market in Latin America for Nuclear Reactors, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
27.5.2. Radiopharmaceuticals Market in Latin America for Accelerators / Cyclotrons, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
27.5.3. Radiopharmaceuticals Market in Latin America for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
27.6. Radiopharmaceuticals Market in Latin America: Distribution by Therapeutic Area
27.6.1. Radiopharmaceuticals Market in Latin America for Oncological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
27.6.2. Radiopharmaceuticals Market in Latin America for Cardiovascular Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
27.6.3. Radiopharmaceuticals Market in Latin America for Neurological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
27.6.4. Radiopharmaceuticals Market in Latin America for Hormonal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
27.6.5. Radiopharmaceuticals Market in Latin America for Gastrointestinal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
27.6.6. Radiopharmaceuticals Market in Latin America for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
27.7. Radiopharmaceuticals Market in Latin America: Distribution by End-user
27.7.1. Radiopharmaceuticals Market in Latin America for Hospitals, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
27.7.2. Radiopharmaceuticals Market in Latin America for Diagnostic Centers, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
27.7.3. Radiopharmaceuticals Market in Latin America for Research Institutes, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
28.1 Radiopharmaceuticals Market in Middle East and North Africa: Distribution by Type of Radioisotope
28.1.1. Radiopharmaceuticals Market in Middle East and North Africa for Technetium-99m, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
28.1.2. Radiopharmaceuticals Market in Middle East and North Africa for Leutetium-177, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
28.1.3. Radiopharmaceuticals Market in Middle East and North Africa for Fluorine-18, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
28.1.4. Radiopharmaceuticals Market in Middle East and North Africa for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
28.2. Radiopharmaceuticals Market in Middle East and North Africa: Distribution by Type of Emitter
28.2.1. Radiopharmaceuticals Market in Middle East and North Africa for Gamma Emitters, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
28.2.2. Radiopharmaceuticals Market in Middle East and North Africa for Beta Emitters, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
28.2.3. Radiopharmaceuticals Market in Middle East and North Africa for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
28.3. Radiopharmaceuticals Market in Middle East and North Africa: Distribution by Purpose of Radiopharmaceutical
28.3.1. Radiopharmaceuticals Market in Middle East and North Africa for Diagnostics, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
28.3.2. Radiopharmaceuticals Market in Middle East and North Africa for Therapeutics, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
28.4. Radiopharmaceuticals Market in Middle East and North Africa: Distribution by Type of Diagnostic Radiopharmaceutical
28.4.1. Radiopharmaceuticals Market in Middle East and North Africa for PET Imaging Agents, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
28.4.2. Radiopharmaceuticals Market in Middle East and North Africa for SPECT Imaging Agents, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
28.5. Radiopharmaceuticals Market in Middle East and North Africa: Distribution by Type of Production Method
28.5.1. Radiopharmaceuticals Market in Middle East and North Africa for Nuclear Reactors, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
28.5.2. Radiopharmaceuticals Market in Middle East and North Africa for Accelerators / Cyclotrons, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
28.5.3. Radiopharmaceuticals Market in Middle East and North Africa for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
28.6. Radiopharmaceuticals Market in Middle East and North Africa: Distribution by Therapeutic Area
28.6.1. Radiopharmaceuticals Market in Middle East and North Africa for Oncological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
28.6.2. Radiopharmaceuticals Market in Middle East and North Africa for Cardiovascular Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
28.6.3. Radiopharmaceuticals Market in Middle East and North Africa for Neurological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
28.6.4. Radiopharmaceuticals Market in Middle East and North Africa for Hormonal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
28.6.5. Radiopharmaceuticals Market in Middle East and North Africa for Gastrointestinal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
28.6.6. Radiopharmaceuticals Market in Middle East and North Africa for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
28.7. Radiopharmaceuticals Market in Middle East and North Africa: Distribution by End-user
28.7.1. Radiopharmaceuticals Market in Middle East and North Africa for Hospitals, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
28.7.2. Radiopharmaceuticals Market in Middle East and North Africa for Diagnostic Centers, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
28.7.3. Radiopharmaceuticals Market in Middle East and North Africa for Research Institutes, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
29.1. Brief Overview of Processes and Stakeholders Involved
29.2. Schematic Representation of Radiopharmaceuticals Synthesis Process
29.3. Key Challenges and Mitigation Strategies
31.1. Chapter Overview
31.2. Company A
31.2.1. Company Snapshot
31.2.2. Interview Transcript: Chief Executive Officer, Small Company
31.3. Company B
31.3.1. Company Snapshot
31.3.2. Interview Transcript: Chief Executive Officer, Very Small Company
31.4. Company C
31.4.1. Company Snapshot
31.4.2. Interview Transcript: Chief Executive Officer, Mid-Sized Company
31.5. Company D
31.5.1. Company Snapshot
31.5.2. Interview Transcript: Chief Executive Officer, Large Company
31.6. Company E
31.6.1. Company Snapshot
31.6.2. Interview Transcript: Chair, Department of Radiology, Large Organization
31.7. Company F
31.7.1. Company Snapshot
31.7.2. Interview Transcript: President, Mid-Sized Company
31.8. Company G
31.8.1. Company Snapshot
31.8.2. Interview Transcript: Vice President, Clinical Development, Large Organization
31.9. Company H
31.9.1. Company Snapshot
31.9.2. Interview Transcript: Medical Director, Mid-Sized Company
31.10. Company I
31.10.1. Company Snapshot
31.10.2. Interview Transcript: Radiation Oncologist and Co-director, Very Large Organization
31.11. Company J
31.11.1. Company Snapshot
31.11.2. Interview Transcript: Doctor of Medicine, Very Large Organization
Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Market Assessment Framework
Figure 3.3 Market Dynamics: Example List of Parameters
Figure 4.1 Historical Analysis of Past Recessions and Lessons Learnt
Figure 5.1 Executive Summary: Market Landscape
Figure 5.2 Executive Summary: Market Trends
Figure 5.3 Executive Summary: Market Sizing and Opportunity Analysis
Figure 6.1 Mechanism of Action of Radiopharmaceuticals
Figure 6.2 Advantages of Radiopharmaceuticals
Figure 8.1 Approved Radiopharmaceutical Therapy Programs: Distribution by Format of Radiopharmaceutical
Figure 8.2 Approved Radiopharmaceutical Therapy Programs: Distribution by Type of Radioisotope
Figure 8.3 Approved Radiopharmaceutical Therapy Programs: Distribution by Type of Emitter
Figure 8.4 Approved Radiopharmaceutical Therapy Programs: Distribution by Purpose of Radiopharmaceutical
Figure 8.5 Approved Radiopharmaceutical Therapy Programs: Distribution by Therapeutic Area
Figure 8.6 Approved Radiopharmaceutical Therapy Programs: Distribution by Target Indication
Figure 8.7 Approved Radiopharmaceutical Therapy Programs: Distribution by Route of Administration
Figure 8.8 Approved Radiopharmaceutical Therapy Programs: Distribution by Dosage Frequency
Figure 8.9 Approved Radiopharmaceutical Developers: Distribution by Year of Establishment and Location of Headquarters
Figure 8.10 Approved Radiopharmaceutical Developers: Distribution by Company Size and Year of Establishment
Figure 8.11 Approved Radiopharmaceutical Developers: Distribution by Location of Headquarters Company Size
Figure 8.12 Most Active Players: Distribution by Number of Approved Radiopharmaceuticals
Figure 9.1 Clinical and Preclinical Radiopharmaceutical Therapy Programs: Distribution by Stage of Development
Figure 9.2 Clinical and Preclinical Radiopharmaceutical Therapy Programs: Distribution by Type of Radioisotope
Figure 9.3 Clinical and Preclinical Radiopharmaceutical Therapy Programs: Distribution by Type of Emitter
Figure 9.4 Clinical and Preclinical Radiopharmaceutical Therapy Programs: Distribution by Purpose of Radiopharmaceutical
Figure 9.5 Clinical and Preclinical Radiopharmaceutical Therapy Programs: Distribution by Type of Therapy
Figure 9.6 Clinical and Preclinical Radiopharmaceutical Therapy Programs: Distribution by Route of Administration
Figure 9.7 Clinical and Preclinical Radiopharmaceutical Therapy Programs: Distribution by Target Indication
Figure 9.8 Clinical and Preclinical Radiopharmaceutical Therapy Programs: Distribution by Therapeutic Area
Figure 9.9 Clinical and Preclinical Radiopharmaceutical Therapy Programs: Distribution by Target Patient Population
Figure 9.10 Clinical and Preclinical Radiopharmaceutical Developers: Distribution by Year of Establishment and Location of Headquarters
Figure 9.11 Clinical and Preclinical Radiopharmaceutical Developers: Distribution by Company Size and Year of Establishment
Figure 9.12 Clinical and Preclinical Radiopharmaceutical Developers: Distribution by Location of Headquarters Company Size
Figure 9.13 Most Active Players: Distribution by Number of Clinical and Preclinical Radiopharmaceuticals
Figure 11.1 Partnerships and Collaborations: Analysis by Year of Partnership
Figure 11.2 Partnerships and Collaborations: Analysis by Type of Partnership
Figure 11.3 Partnerships and Collaborations: Analysis by Year and Type of Partnership
Figure 11.4 Partnerships and Collaborations: Analysis by Type of Radioisotope
Figure 11.5 Partnerships and Collaborations: Analysis by Type of Emission
Figure 11.6 Partnerships and Collaborations: Analysis by Type of Molecule
Figure 11.7 Partnerships and Collaborations: Analysis by Therapeutic Area
Figure 11.8 Partnerships and Collaborations: Analysis by Purpose of Radiopharmaceutical
Figure 11.9 Partnerships and Collaborations: Analysis by Type of Partner
Figure 11.10 Most Active Players: Analysis by Number of Partnerships
Figure 11.11 Partnerships and Collaborations: Analysis by Local and International Agreements
Figure 11.12 Partnerships and Collaborations: Analysis by Intercontinental and Intracontinental Agreements
Figure 12.1 Clinical Trial Analysis: Analysis by Trial Registration Year
Figure 12.2 Clinical Trial Analysis: Analysis by Analysis by Trial Status
Figure 12.3 Clinical Trial Analysis: Analysis by Trial Registration Year and Trial Status
Figure 12.4 Clinical Trial Analysis: Analysis of Patient Enrolled by Trial Registration Year
Figure 12.5 Clinical Trial Analysis: Analysis by Trial Phase
Figure 12.6 Clinical Trial Analysis: Analysis of Patient Enrolled by Trial Phase
Figure 12.7 Clinical Trial Analysis: Analysis by Type of Sponsor / Collaborator
Figure 12.8 Clinical Trial Analysis: Analysis by Study Design
Figure 12.9 Clinical Trial Analysis: Analysis by Patient Gender
Figure 12.10 Clinical Trial Analysis: Analysis by Target Patient Population
Figure 12.11 Most Active Industry Players: Analysis by Number of Clinical Trials
Figure 12.12 Most Active Non- Industry Players: Analysis by Number of Clinical Trials
Figure 12.13 Geographical Distribution: Analysis by Number of Trials and Patients Enrolled
Figure 12.14 Clinical Trial Analysis: Analysis by Trial Status and Geography
Figure 12.15 Clinical Trial Analysis: Analysis of` Patients Enrolled by Trial Status and Geography
Figure 13.1 Megatrend Analysis: An Overview of Emerging Trends
Figure 15.1 Global Radiopharmaceuticals Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040), Scenario Analysis
Figure 15.2 Global Radiopharmaceuticals Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040), Conservative Scenario
Figure 15.3 Global Radiopharmaceuticals Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040), Optimistic Scenario
Figure 16.1 Radiopharmaceuticals Market for Technetium-99m, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 16.2 Radiopharmaceuticals Market for Leutetium-177, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 16.3 Radiopharmaceuticals Market for Fluorine-18, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 16.4 Radiopharmaceuticals Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 17.1 Radiopharmaceuticals Market for Gamma Emitters, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 17.2 Radiopharmaceuticals Market for Beta Emitters, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 17.3 Radiopharmaceuticals Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 18.1 Radiopharmaceuticals Market for Diagnostics, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 18.2 Radiopharmaceuticals Market for Therapeutics, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 19.1 Radiopharmaceuticals Market for PET Imaging Agents, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 19.2 Radiopharmaceuticals Market for SPECT Imaging Agents, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 20.1 Radiopharmaceuticals Market for Nuclear Reactors, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 20.2 Radiopharmaceuticals Market for Accelerators / Cyclotrons, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 20.3 Radiopharmaceuticals Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 21.1 Radiopharmaceuticals Market for Oncological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 21.2 Radiopharmaceuticals Market for Cardiovascular Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 21.3 Radiopharmaceuticals Market for Neurological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 21.4 Radiopharmaceuticals Market for Hormonal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 21.5 Radiopharmaceuticals Market for Gastrointestinal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 21.6 Radiopharmaceuticals Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 21.7 Radiopharmaceuticals Market for Hospitals, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 21.8 Radiopharmaceuticals Market for Diagnostic Centers, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 21.9 Radiopharmaceuticals Market for Research Institutes, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 23.1 Radiopharmaceuticals Market: Distribution by Geographical Regions
Figure 23.2 Radiopharmaceuticals Market in North America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 23.3 Radiopharmaceuticals Market in the US, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 23.4 Radiopharmaceuticals Market in Canada, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 23.5 Radiopharmaceuticals Market in Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 23.6 Radiopharmaceuticals Market in Germany, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 23.7 Radiopharmaceuticals Market in France, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 23.8 Radiopharmaceuticals Market in Spain, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 23.9 Radiopharmaceuticals Market in the Italy, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 23.10 Radiopharmaceuticals Market in the UK, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 23.11 Radiopharmaceuticals Market in Rest of Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 23.12 Radiopharmaceuticals Market in Asia-Pacific, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 23.13 Radiopharmaceuticals Market in Australia, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 23.14 Radiopharmaceuticals Market in China, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 23.15 Radiopharmaceuticals Market in Japan, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 23.16 Radiopharmaceuticals Market in India, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 23.17 Radiopharmaceuticals Market in South Korea, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 23.18 Radiopharmaceuticals Market in Rest of Asia-Pacific, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 23.19 Radiopharmaceuticals Market in Latin America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 23.20 Radiopharmaceuticals Market in Brazil, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 23.21 Radiopharmaceuticals Market in Rest of Latin America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 23.22 Radiopharmaceuticals Market in Middle East and North Africa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 23.23 Radiopharmaceuticals Market in Israel, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 23.24 Radiopharmaceuticals Market in South Africa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 23.25 Radiopharmaceuticals Market in Rest of Middle East and North Africa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Figure 24.1 Supply Chain Analysis: Brief Overview of Processes and Stakeholders Involved
Table 8.1 List of Approved Radiopharmaceutical Therapy Programs
Table 8.2 List of Approved Radiopharmaceutical Developers
Table 9.1 List of Clinical and Preclinical Radiopharmaceutical Therapy Programs
Table 9.2 List of Clinical and Preclinical Radiopharmaceutical Developers
Table 10.1 3B Pharmaceuticals: Company Overview
Table 10.2 3B Pharmaceuticals: Radiopharmaceuticals Pipeline
Table 10.3 3B Pharmaceuticals: Recent Initiatives
Table 10.4 Curium Pharma: Company Overview
Table 10.5 Curium Pharma: Radiopharmaceuticals Pipeline
Table 10.6 Curium Pharma: Recent Initiatives
Table 10.7 ITM Radiopharma: Company Overview
Table 10.8 ITM Radiopharma: Radiopharmaceuticals Pipeline
Table 10.9 ITM Radiopharma: Recent Initiatives
Table 10.10 Jubilant Radiopharma: Company Overview
Table 10.11 Jubilant Radiopharma: Radiopharmaceuticals Pipeline
Table 10.12 Jubilant Radiopharma: Recent Initiatives
Table 10.13 Lantheus: Company Overview
Table 10.14 Lantheus: Radiopharmaceuticals Pipeline
Table 10.15 Lantheus: Recent Initiatives
Table 10.16 Yantai LNC Biotechnology: Company Overview
Table 10.17 Yantai LNC Biotechnology: Radiopharmaceuticals Pipeline
Table 10.18 Yantai LNC Biotechnology: Recent Initiatives
Table 10.19 Norroy Biosciences: Company Overview
Table 10.20 Norroy Biosciences: Radiopharmaceuticals Pipeline
Table 10.21 Norroy Biosciences: Recent Initiatives
Table 10.22 Sinotau Pharmaceutical: Company Overview
Table 10.23 Sinotau Pharmaceutical: Radiopharmaceuticals Pipeline
Table 10.24 Sinotau Pharmaceutical: Recent Initiatives
Table 10.25 Telix Pharmaceuticals: Company Overview
Table 10.26 Telix Pharmaceuticals: Radiopharmaceuticals Pipeline
Table 10.27 Telix Pharmaceuticals: Recent Initiatives
Table 11.1 Radiopharmaceuticals: List of Partnerships and Collaborations, Since 2021
Table 11.2 Radiopharmaceuticals: List of Clinical Trials, Since 2021
Table 26.1 Approved Radiopharmaceutical Therapy Programs: Distribution by Format of Radiopharmaceutical
Table 26.2 Approved Radiopharmaceutical Therapy Programs: Distribution by Type of Radioisotope
Table 26.3 Approved Radiopharmaceutical Therapy Programs: Distribution by Type of Emitter
Table 26.4 Approved Radiopharmaceutical Therapy Programs: Distribution by Purpose of Radiopharmaceutical
Table 26.5 Approved Radiopharmaceutical Therapy Programs: Distribution by Therapeutic Area
Table 26.6 Approved Radiopharmaceutical Therapy Programs: Distribution by Target Indication
Table 26.7 Approved Radiopharmaceutical Therapy Programs: Distribution by Route of Administration
Table 26.8 Approved Radiopharmaceutical Therapy Programs: Distribution by Dosage Frequency
Table 26.9 Approved Radiopharmaceutical Developers: Distribution by Year of Establishment
Table 26.10 Approved Radiopharmaceutical Developers: Distribution by Company Size
Table 26.11 Approved Radiopharmaceutical Developers: Distribution by Location of Headquarters
Table 26.12 Most Active Players: Distribution by Number of Approved Radiopharmaceuticals
Table 26.13 Clinical and Preclinical Radiopharmaceutical Therapy Programs: Distribution by Stage of Development
Table 26.14 Clinical and Preclinical Radiopharmaceutical Therapy Programs: Distribution by Type of Radioisotope
Table 26.15 Clinical and Preclinical Radiopharmaceutical Therapy Programs: Distribution by Type of Emitter
Table 26.16 Clinical and Preclinical Radiopharmaceutical Therapy Programs: Distribution by Purpose of Radiopharmaceutical
Table 26.17 Clinical and Preclinical Radiopharmaceutical Therapy Programs: Distribution by Type of Therapy
Table 26.18 Clinical and Preclinical Radiopharmaceutical Therapy Programs: Distribution by Route of Administration
Table 26.19 Clinical and Preclinical Radiopharmaceutical Therapy Programs: Distribution by Target Indication
Table 26.20 Clinical and Preclinical Radiopharmaceutical Therapy Programs: Distribution by Therapeutic Area
Table 26.21 Clinical and Preclinical Radiopharmaceutical Therapy Programs: Distribution by Target Patient Population
Table 26.22 Clinical and Preclinical Radiopharmaceutical Developers: Distribution by Year of Establishment
Table 26.23 Clinical and Preclinical Radiopharmaceutical Developers: Distribution by Company Size
Table 26.24 Clinical and Preclinical Radiopharmaceutical Developers: Distribution by Location of Headquarters
Table 26.25 Most Active Players: Distribution by Number of Clinical and Preclinical Radiopharmaceuticals
Table 26.26 Partnerships and Collaborations: Analysis by Year of Partnership
Table 26.27 Partnerships and Collaborations: Analysis by Type of Partnership
Table 26.28 Partnerships and Collaborations: Analysis by Year and Type of Partnership
Table 26.29 Partnerships and Collaborations: Analysis by Type of Radioisotope
Table 26.30 Partnerships and Collaborations: Analysis by Type of Emission
Table 26.31 Partnerships and Collaborations: Analysis by Type of Molecule
Table 26.32 Partnerships and Collaborations: Analysis by Therapeutic Area
Table 26.33 Partnerships and Collaborations: Analysis by Purpose of Radiopharmaceutical
Table 26.34 Partnerships and Collaborations: Analysis by Type of Partner
Table 26.35 Most Active Players: Analysis by Number of Partnerships
Table 26.36 Partnerships and Collaborations: Analysis by Local and International Agreements
Table 26.37 Partnerships and Collaborations: Analysis by Intercontinental and Intracontinental Agreements
Table 26.38 Clinical Trial Analysis: Analysis by Trial Registration Year
Table 26.39 Clinical Trial Analysis: Analysis by Analysis by Trial Status
Table 26.40 Clinical Trial Analysis: Analysis by Trial Registration Year and Trial Status
Table 26.41 Clinical Trial Analysis: Analysis of Patient Enrolled by Trial Registration Year
Table 26.42 Clinical Trial Analysis: Analysis by Trial Phase
Table 26.43 Clinical Trial Analysis: Analysis of Patient Enrolled by Trial Phase
Table 26.44 Clinical Trial Analysis: Analysis by Type of Sponsor / Collaborator
Table 26.45 Clinical Trial Analysis: Analysis by Study Design
Table 26.46 Clinical Trial Analysis: Analysis by Patient Gender
Table 26.47 Clinical Trial Analysis: Analysis by Target Patient Population
Table 26.48 Most Active Industry Players: Analysis by Number of Clinical Trials
Table 26.49 Most Active Non- Industry Players: Analysis by Number of Clinical Trials
Table 26.50 Geographical Distribution: Analysis by Number of Trials and Patients Enrolled
Table 26.51 Clinical Trial Analysis: Analysis by Trial Status and Geography
Table 26.52 Clinical Trial Analysis: Analysis of` Patients Enrolled by Trial Status and Geography
Table 26.53 Global Radiopharmaceuticals Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040), Scenario Analysis
Table 26.54 Global Radiopharmaceuticals Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040), Conservative Scenario
Table 26.55 Global Radiopharmaceuticals Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040), Optimistic Scenario
Table 26.56 Global Radiopharmaceuticals Market, Analysis by Type of Radioisotope
Table 26.57 Radiopharmaceuticals Market for Technetium-99m, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Table 26.58 Radiopharmaceuticals Market for Leutetium-177, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Table 26.59 Radiopharmaceuticals Market for Fluorine-18, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Table 26.60 Radiopharmaceuticals Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Table 26.61 Global Radiopharmaceuticals Market, Analysis by Type of Emitter
Table 26.62 Radiopharmaceuticals Market for Gamma Emitters, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Table 26.63 Radiopharmaceuticals Market for Beta Emitters, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Table 26.64 Radiopharmaceuticals Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Table 26.65 Global Radiopharmaceuticals Market, Analysis by Purpose of Radiopharmaceuticals
Table 26.66 Radiopharmaceuticals Market for Diagnostics, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Table 26.67 Radiopharmaceuticals Market for Therapeutics, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Table 26.68 Global Radiopharmaceuticals Market, Analysis by Type of Diagnostic Radiopharmaceutical
Table 26.69 Radiopharmaceuticals Market for PET Imaging Agents, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Table 26.70 Radiopharmaceuticals Market for SPECT Imaging Agents, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Table 26.71 Global Radiopharmaceuticals Market, Analysis by Type of Production Method
Table 26.72 Radiopharmaceuticals Market for Nuclear Reactors, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Table 26.73 Radiopharmaceuticals Market for Accelerators / Cyclotrons, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Table 26.74 Radiopharmaceuticals Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Table 26.75 Global Radiopharmaceuticals Market, Analysis by Therapeutic Area
Table 26.76 Radiopharmaceuticals Market for Oncological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Table 26.77 Radiopharmaceuticals Market for Cardiovascular Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Table 26.78 Radiopharmaceuticals Market for Neurological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Table 26.79 Radiopharmaceuticals Market for Hormonal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Table 26.80 Radiopharmaceuticals Market for Gastrointestinal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Table 26.81 Radiopharmaceuticals Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Table 26.82 Global Radiopharmaceuticals Market, Analysis by End User
Table 26.83 Radiopharmaceuticals Market for Hospitals, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Table 26.84 Radiopharmaceuticals Market for Diagnostic Centers, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Table 26.85 Radiopharmaceuticals Market for Research Institutes, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Table 26.86 Global Radiopharmaceuticals Market, Analysis by Geographical Regions
Table 26.87 Radiopharmaceuticals Market in North America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Table 26.88 Radiopharmaceuticals Market in the US, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Table 26.89 Radiopharmaceuticals Market in Canada, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Table 26.90 Radiopharmaceuticals Market in Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Table 26.91 Radiopharmaceuticals Market in Germany, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Table 26.92 Radiopharmaceuticals Market in France, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Table 26.93 Radiopharmaceuticals Market in Spain, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Table 26.94 Radiopharmaceuticals Market in the Italy, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Table 26.95 Radiopharmaceuticals Market in UK, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Table 26.96 Radiopharmaceuticals Market in Rest of Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Table 26.97 Radiopharmaceuticals Market in Asia-Pacific, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Table 26.98 Radiopharmaceuticals Market in Australia, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Table 26.99 Radiopharmaceuticals Market in China, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Table 26.100 Radiopharmaceuticals Market in Japan, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Table 26.101 Radiopharmaceuticals Market in India, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Table 26.102 Radiopharmaceuticals Market in South Korea, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Table 26.103 Radiopharmaceuticals Market in Rest of Asia-Pacific, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Table 26.104 Radiopharmaceuticals Market in Latin America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Table 26.105 Radiopharmaceuticals Market in Brazil, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Table 26.106 Radiopharmaceuticals Market in Rest of Latin America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Table 26.107 Radiopharmaceuticals Market in Middle East and North Africa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Table 26.108 Radiopharmaceuticals Market in Israel, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Table 26.109 Radiopharmaceuticals Market in South Africa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
Table 26.110 Radiopharmaceuticals Market in Rest of Middle East and North Africa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)






Download Free Sample
Buy Now




